Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857497 | 0.85 | CTSK (0.55) | CTSK | |
| SCHEMBL15613759 | 0.85 | CTSK (0.55) | CTSK | |
| SCHEMBL12607856 | 0.83 | CTSK (0.57) | CTSK | |
| SCHEMBL26390143 | 0.83 | PLA2G2C (0.40) | CTSKPLA2G2CSMN1; SMN2 | |
| SCHEMBL1647047 | 0.82 | PPARA (0.49) | CTSKPLA2G2CSMN1; SMN2 | |
| SCHEMBL1647050 | 0.82 | PPARA (0.49) | CTSKPLA2G2CSMN1; SMN2 | |
| SCHEMBL10274067 | 0.81 | CTSK (0.57) | CTSK | |
| SCHEMBL6032007 | 0.81 | SMN1; SMN2 (0.44) | CTSKPLA2G2CSMN1; SMN2 | |
| SCHEMBL27762620 | 0.81 | SMN1; SMN2 (0.44) | CTSKPLA2G2CSMN1; SMN2 | |
| SCHEMBL24963649 | 0.78 | CTSK (0.62) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | CTSK 593/4885PLA2G2C 997/4885SMN1; SMN2 4802/4885 |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, VIP | CTSK 390/4885PLA2G2C 522/4885SMN1; SMN2 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.